Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 6, 2008, Pages 764-769

  van den Elskamp, I J ^a,e   Lembcke, J ^c   Dattola, V ^a,b   Beckmann, K ^b   Pohl, C ^c,d   Hong, W ^c   Sandbrink, R ^c   Wagner, K ^c   Knol, D L ^a   Uitdehaag, B ^a   Barkhof, F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MESSINA   (Italy)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e NONE   (Netherlands)

Author keywords

MRI; Negative binomial distribution; Persistent black hole; Sample size

Indexed keywords

BETA1A INTERFERON; GADOLINIUM PENTETATE; NEOPTERIN; PLACEBO;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BINOMIAL DISTRIBUTION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; IMAGE DISPLAY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERSISTENT BLACK HOLE; PHASE 2 CLINICAL TRIAL; POWER ANALYSIS; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; CONTRAST MEDIA; DRUG MONITORING; GADOLINIUM DTPA; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MODELS, STATISTICAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 48349109469     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507087842     Document Type: Article

References (15)

1. Miller, DH, Barkhof, F, Nauta, JJP. Gadolinium enhancement increases the sensitivity of MRI detecting disease activity in MS. Brain 1993; 116: 1077-1094.
2. McFarland, HF, Frank, JA, Albert, PS, Smith, ME, Martin, R, Harris, JO, et al. Using gadolinium enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758-766.
3. Bruck, W, Bitsch, A, Kolenda, H, Bruck, Y, Stiefel, M, Lassmann, H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-793.
4. Van Walderveen, MA, Kamphorst, Scheltens, P, van Waesberghe, JH, Ravid, R, Valk, J, et al. Histopathologic correlate of hypointense lesions on T1-weighted spinecho MRI in multiple sclerosis. Neurology 1998; 50:1282-1288.
5. van Waesberghe, JH, Kamphorst, W, De Groot, CJ, van Walderveen, MA, Castelijns, JA, Ravid, R, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46: 747-754.
6. Bitsch, A, Kuhlmann, T, Stadelman C, Lassmann, H, Lucchinetti, C, Bruck, W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001; 49: 793-796.
7. van Waesberghe, JH, van Walderveen MA, Castelijns, JA, Scheltens, P. Lycklama, Nijeholt, GJ, Polman, CH, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin echo and magnetization transfer MR. Am J Neuroradiol 1998; 19: 675-683.
8. Polman, C, Barkhof, F, Kappos, L, Pozzilli, C, Sandbrink, R, Dahlke, F, et al. and the European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003; 9: 342-348.
9. Sormani, MP, Bruzzi, P, Rovaris, M, Barkhof, F, Comi, G, Miller, DH, et al. Modelling new enhancing MRI lesion counts in multiple sclerosis. Mult Scler 2001; 7: 298-304.
10. Agresti, A. Categorical data analysis, second edition. New York: Wiley; 2002. p. 559-560.
11. Sormani, MP, Miller, DH, Comi, G, Barkhof, F, Rovarins, M, Bruzzi, P, et al. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large datasets. J Neurol Neurosurg Psychiatry 2001; 70: 494-499.
12. Brex, PA, Molyneux, PD, Smiddy, P, Barkhof, F, Filippi, M, Yousry, TA, et al. and the European Study Group on Interferon Beta-1b in Secondary Progressive MS. The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001; 57: 2185-2190.
13. Ciccarelli, O, Giugni, E, Paolillo, A, Mainero, C, Gasperini, C, Bastianello, S, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999; 6: 455-459.
14. Bagnato, F, Jeffries, N, Richert, ND, Stone, RD, Ohayon, JM, McFarland, HF, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003; 126: 1782-1789.
15. Minneboo, A, Uitdehaag, BMJ, Ader, HJ, Barkhof, F, Polman, CH, Castelijns, JA. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology 2005; 65: 56-60.